



BIO International Convention French Pavilion

June 22-25, 2026





The French Pavilion by Business France

The French Pavilion at BIO International Convention 2026 brings together **100+ pioneering French companies** at the forefront of the life sciences industry. This collective presence highlights the vitality of France's biotech and healthcare ecosystems, presenting cutting-edge technologies, groundbreaking research, and high-potential partnerships.

Spearheaded by Business France, the national agency for the international development of the French economy, this initiative boosts France's global visibility and promotes strategic collaborations between French innovators and international stakeholders.

From agile startups to industry leaders, the Pavilion represents a broad spectrum of expertise - from biopharmaceuticals and life sciences services to medical technologies and research institutions. It serves as a dynamic hub for networking, business development, and knowledge sharing - reflecting France's commitment to advancing global health and life sciences innovation.

TRADE WITH FRANCE

With an extensive network of representatives in France, Business France is the fastest, most efficient way to source French innovative solutions and outstanding technologies.

INVEST IN FRANCE

Business France provides guidance for North American companies looking to bank on France's R&D, clusters, and business environment to set up or extend their European network.



The French Pavilion at the BIO International Convention is far more than a networking space — it's where concrete collaborations take shape, strategic discussions turn into licensing deals, and innovation moves toward international scale-up. As a key bridge between the French and U.S. healthcare ecosystems, the Pavilion reflects the mission of Business France and French Healthcare: bringing together a strong delegation of French biotechs, medtechs, CROs and service providers with U.S. pharma companies, investors, hospitals, industry leaders and key opinion leaders to build high-value partnerships that accelerate U.S. market entry and fuel international growth.

Each year, BIO serves as a pivotal milestone for French life sciences companies looking to scale internationally and expand their footprint in the U.S. The French Pavilion plays a central role in this dynamic, enabling targeted business meetings and fostering direct connections that often lead to licensing agreements and long-term collaborations across the Atlantic.

The momentum continues to grow year after year — and we're only getting started. Let's make 2026 our most impactful edition yet.

See you in sunny San Diego!

Jérôme Revole

Healthcare and Life Sciences Director



Table of contents

BIOTECH & PHARMA

Aceso Therapeutics	Cystic Fibrosis	Rare diseases	Respiratory	16	Hemerion Therapeutics	Oncology	CNS	Brain Tumor	More	26
ADOCIA	Obesity	Diabetes		16	HEPHAISTOS	Oncology				27
Affilogic	CNS Diseases	Oncology	IBD	More	17	Igyxos	Infertility			27
AlgenScribe	Gene therapy	Oncology		17	InSpek	Oncology	Vaccine	Innovative therapy		28
Antelope Therapeutics	Oncology	Colorectal Cancer	Pancreatic Cancer	18	Kahimmune Therapeutics	Oncology				28
AUROBAC THERAPEUTICS	Infectious diseases	Antimicrobial Resistance	Sepsis	18	Lys Therapeutics	Neurology	CNS	Blood-brain Barrier	Neuroinflammation	29
Averoa	Nephrology	Metabolic diseases	Urology	19	Mabqi	Oncology	Antibodies	ADC		29
Biomunex Pharmaceuticals	Immuno-Oncology	Inflammatory Diseases		19	Medincell	CNS	More			30
BIOPHTA	Ophtalmology	Retina	Glaucoma	20	Netris Pharma	Oncology	Endometriosis	Fibrosis		30
Brenus Pharma	Immuno-oncology	Solid tumors		20	NFL Biosciences	Neurology	Addictions			31
Collectis	Oncology	Cell Therapy	CAR-T	21	Nicox	Ophtalmology				31
Ceres Brain Therapeutics	CNS	Neurology	Rare diseases	21	Oncodesign Precision Medicine	Oncology	Parkinson's disease	Inflammatory		32
Cevibra	Market access	Oncology	Rare diseases	Infectiology	22	ONCOVITA	Oncology	Vaccines		32
Cilcare	Otology	Cognition	Ageing	22	OSE Immunotherapeutics	Oncology	Immunology	Inflammatory		33
Covalab	Oncology	mAb Development	ADC	Agrofood	23	SITERA Pharmaceuticals	Neurodegenerative Diseases	Metabolic diseases		33
Curlim	Neurology	Rare diseases		23	SKINOSIVE	Skin protection	Skin cancer prevention			34
Deeptope	Therapeutic proteins	Antibodies	Epitope mapping	24	SoteriaBio	Respiratory	Drug delivery			34
Dolinnov	Chronic Pain	Neuropathic pain	Inflammatory Pain	Metastatic Cancer Pain	24	Syndivia	Oncology			35
Enemsa Pharma	Neurodegenerative Diseases	Cardiopulmonary Diseases		25	Théa Open Innovation	Ophtalmology				35
Exeliom Biosciences	Oncology	Infectious diseases	IBD	25	THX Pharma	Neurology	Rare diseases			36
H.A.C Pharma	Neurology	Onco-hematology	Endocrinology	Rare diseases	26	Vect-Horus	Oncology	CNS	Skeletal and Cardiac Muscles	36

Table of contents

CRO & CDMO

ALPX	TPD Small Molecules Molecular glues More	37
Antineo	Oncology Immunology	37
Astrum	Oncology Immunology CNS	38
Atlantic Bone Screen	Osteoarticular Inflammatory Oncology More	38
Cenexi	Oncology Immunology Rare diseases	39
Chelatec	Oncology	39
CYTOO	Muscle Kidney Cardiology	40
DIVA Expertise	Metabolic diseases Obesity Skin disorders More	40
ETAP-Lab	Neurology Dermatology Cardiology	41
Eurofins Optimed	CNS Cardiology Oncology More	41
Firalis Molecular Precision	Neurology Oncology More	42
Iris Pharma	Ophthalmology	42
LFB Biomanufacturing	Immunology Rare Diseases Haemostasis Intensive Care	43
Motac Neuroscience	Neurodegenerative Diseases Rare Diseases CNS More	43
Neuron Experts	Rare diseases Alzheimer's Parkinson's ALS	44
Novalix	Oncology Kidney Immunology More	44
Oxeltis	Oncology Inflammatory Infectious diseases	45
Phinc Development	Oncology Rare diseases Immunology	45
Porsolt	CNS Pain Inflammatory Metabolism disorders Obesity More	46
QIMA Life Sciences	Dermatology Immunology Inflammatory Oncology	46
Roowin	cGMP Chemistry Analytical	47
SEQENS	All therapeutic areas	47

TECHBIO

AgenT	Neurodegenerative diseases Alzheimer's Parkinson's	48
AQEMIA	Oncology Neurology CNS	48
BIOHIVE	Dermatology Rare genetic disorders Inflammatory	49
bYoRNA	Oncology Rare diseases Infectious diseases	49
DeepLife	Autoimmune diseases Neurodegenerative diseases Cardio metabolic More	50
MABSilico	Oncology Infectious diseases Inflammatory	50
NETRI	Oncology Dermatology Neurology More	51
Owkin	AI Oncology I & I Neurology	51
Theremia	Neurology Psychiatry CNS	52
WhiteLab Genomics	Genomics Medicine Gene Therapy Cell Therapy	52

MEDTECH

Aurora Sterilisation	Sterilization Endoscopy Medical Devices	53
NG Biotech	Infectious diseases Women's health Antimicrobial Resistance	53

SERVICES

AzurBio Pharma	EU market access Commercialization Pharma launch	54
VCLS	Regulatory strategy Market access Clinical development	54

OTHER INDUSTRY

Dilico	mRNA-LNP manufacturing Continuous Manufacturing Automated Production	55
Etablissement Français du Sang	ATMPs Cell therapy GMP manufacturing	55
Inpart	Partnering intelligence External innovation BD&L platform	56
INSCOPER	Microscopy imaging Super resolution imaging Organoids & 3D models	56

The French Pavilion Partners

A heartfelt thank you to all the partners of the French Pavilion at BIO International Convention 2026 for bringing this collective effort to life.



Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Its pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Ipsen has teams in more than 40 countries and their partnerships around the world allow medicines to be brought to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Philippe Lopes Fernandes

Executive Vice President, Chief Business Officer
philippe.lopes-fernandes@ipsen.com



Natixis Corporate & Investment Banking (part of Groupe BPCE the second largest banking group in France) is a global financial institution offering advisory, financing, and capital markets services. Within Its Corporate & Investment Banking (CIB) division, the Healthcare Sector team supports pharma, MedTech, and healthcare services with deep sector and scientific expertise. Active across Europe, Natixis aims to be the go-to bank for healthcare clients. They focus on three specific areas: pharmaceuticals (big and midcap pharma, biotech), healthcare infrastructure and services (clinics, hospitals, nursing homes, laboratories, CDMO/CMO) and MedTech. We have a global on-the-ground presence and are one of the most active banks within the industry in Europe aiming to become the healthcare "go-to-bank" for our core clients.

Antonin Rigaudière

Managing Director, Global Head of Healthcare Sector
antonin.rigaudiere@natixis.com



DLA Piper is a global law firm with a presence in over 40 countries and more than 90 offices across Europe, the United States, and Asia, and is widely recognized as a leader in Life Sciences and Healthcare. DLA Piper advises pharmaceutical and medical device groups, biotech and medtech companies, and investment funds (VC/PE) on strategic transactions and high stakes matters, including M&A, financings, licensing and collaborations, clinical development, IP strategy and protection, regulatory compliance, and commercialization across the full product lifecycle, through fully integrated, multidisciplinary teams.

Jonathan Rofé

Partner

jonathan.rofe@dlapiper.com



Sonia de Kondserovsky

Partner

sk@dlapiper.com



A major player in regional economic financing, supporting 1 in 5 SME and 1 in 3 mid-sized companies through its 110 Business Centers located across all regions of France and its overseas territories (over \$15 billion in financing by 2024).

More than 38,000 businesses (SMEs, startups, mid-sized companies, and large corporate clients) are supported by our local experts, regardless of their size or industry. Discover our dedicated sales teams: 400 relationship managers working closely with regional ecosystems to support your projects with responsiveness and expertise. A local support system reinforced by experts in cash management, international business, or innovation, for example. Being of service to you also means supporting you on your transformation journey and fully understanding your transition challenges, whether environmental, social, or governance-related. With concrete solutions to meet your needs and support your development projects: Day-to-day management of your cash flows and online payment solutions; Financing for capital expenditures and working capital; Financing for land and real estate in the broadest sense (establishment, relocation, capacity expansion, headquarters, etc.); Financing of investments in production assets (machinery, equipment, IT, etc.) and mobility solutions; Strategic risk management for operations (energy, raw materials, etc.); Support for transformative transactions (external growth, IPOs, etc.); Implementation of insurance, employee savings, and retirement solutions for your employees; Investment of your excess cash; Wealth optimization; Support for your import-export operations and international expansion projects.

Audrey Dubois

Head of Healthcare Sector
audrey.dubois@bpce.fr



Romain Rambaud

Head of Corporate & Innovation Markets
romain.rambaud@bpce.fr



Shahin Gharakhanian MD, DPH, is a Physician-Executive with Expertise in Pharmaceutical Medicine, Leadership and Management, and an international track record. His passion is Patient-focused Programs for Novel Drug & Vaccine Development, Approval and Launch. He aims and strives to add value to Companies, notably by acting as Chief Medical Officer, via SABs (Scientific Advisory Boards) or ad hoc as Program Executive. Dr Gharakhanian has conducted projects with 30 different global companies, 20 different brands and 4 NDA/MAA and/or new drug launches, including a blockbuster in 2011. These involved a variety of therapeutic areas and geographic regions [Asia, Canada, and EU, USA]. Leader-BUILDER with a track record of setting up three fully operational departments, one pharmaceutical company department, one CRO, one academic clinical unit and four LLCs.

Shahin Gharakhanian

Principal & Founder, Executive Consultant
& Chief Medical Officer
shahin.gharakhanian@gmail.com



Efor Group is a global leader in quality and compliance consulting for the Life Sciences industry. With over 3,000 experts across 18 countries, the company supports pharmaceutical, biotechnology, and medical device organizations in securing their manufacturing processes and accelerating time-to-market for innovative therapies.

Efor delivers tailored solutions in CQV, Quality Management, and Engineering Compliance, ensuring regulatory readiness and operational excellence across the entire product lifecycle. By combining technical expertise with flexible delivery models, Efor helps clients overcome complex challenges while maintaining the highest standards of safety and quality.

Mickael Pretot

Executive Director

mickael.pretot@efor-group.com





ICOSA is a European intellectual property firm, founded in 2009, specializing in supporting stakeholders in the Health, Cosmetics, Food, Environment, and Tech industries. We help companies and investors address intellectual property challenges by protecting, securing, and maximizing the value of their innovations worldwide (patents, trademarks, designs, contracts, etc.).

With a team of 90 multidisciplinary professionals, ICOSA combines technical expertise, business vision, and strategic insight to guide clients through every stage of their growth, from start-ups to multinational corporations.

Based in France and Belgium, ICOSA positions itself as a specialist in intellectual property strategy, a trusted partner at the heart of innovation ecosystems, and a key player in creating value across European and global markets.



Caroline de Mareüil-Villette
Founding Partner
cdm@icosa.fr



Claire Verschelde
Founding Partner
cv@icosa.fr



JobsOhio is a private nonprofit corporation wholly funded by an independent private source –the profits from the JobsOhio Beverage System (JOBS) liquor enterprise –that JobsOhio purchased in 2013 and manages today.

JOBS liquor profits provide a stable funding source which allows JobsOhio to utilize a longer-term horizon for funding economic development activities. No public or taxpayer dollars are used

Justin Kocher
Senior Director,
International Business Development
kocher@jobsOhio.com



Jordan Tyler
Manager, North American Business Development
tyler@jobsOhio.com



Orcom is a US based accounting and tax services firm with American Certified Public Accountants (CPAs), ACCA and French diplomes “Experts-comptables” (French CPA licensees). The company’s world-class global team brings together the art of accounting and international taxation with the science of technology to help its clients achieve their business goals. The company drives its mission through a culture of excellence: constantly improving and learning, supporting performance, and succeeding with integrity.

Frédéric V. Blanchard
Managing Partner
fvblanchard@orcomus.com



THE FRENCH ECOSYSTEM

Healthcare Ecosystem & Regions



Atlanpole Biotherapies is a leading health competitiveness cluster for Western France (Brittany, Pays-de-la-Loire, Centre Val-de-Loire), accredited by the French Ministry of Industry in July 2005. The cluster brings together 200 members representing a diverse ecosystem of industrial players, major groups, SMEs, start-ups, research laboratories, university teaching hospitals, universities, and specialized educational institutions. Together, they create a dynamic, competitive ecosystem for healthcare innovations, spanning biomedicine, MedTech, digital health, and disease prevention, with a focus on advancing cutting-edge solutions across these sectors.

Elodie Girardet
Head of European and International Affairs
elodie.girardet@atlanpolebiotherapies.com



BOOST positions itself as a Global Health and DeepTech Campus for Sciences and Industry addressing the OneHealth concept without focusing on any specific pathology “disease-agnostic”. This approach aims to stimulate innovation at the intersection of disciplines such as Pharma/Biotech, TechBio & AI, Quantum as enabling techno to serve the following sub sectors as well as MedTech & Diagnostics, Robotics and Medical Equipment, Food & Agri&Tech and Cosmetics.

Jean-Marc Bourez
Executive Director Boost Campus
jmb@az-am.com



CCI INTERNATIONAL GRAND EST is the international business development operator for companies in the Grand Est region, in France. As a one-stop shop bringing together all the services offered by Team France Export – the French public initiative supporting the internationalization of French companies –, CCI International Grand Est provides tailored solutions to meet the needs of companies seeking to expand internationally. Its team of advisors, in collaboration with Business France, supports companies at every stage of their international development.

Valérie Mottl
International Advisor
v.mottl@grandest.cci.fr



Choose Paris Region is Paris Region's international attractiveness agency, which promotes the region's influence on the international stage, and provides a high-quality welcome and services to investors, visitors and talent from all over the world, while ensuring the Region's sustainable and balanced development.

Yann Masson
Head of HealthTech
yann.masson@chooseparisregion.org



Eurobiomed is the Health Technologies cluster in Southern France, bringing together 400+ members, including over 70% startups and SMEs representing most of the regional entrepreneurial fabric. Eurobiomed's network also includes research institutes, hospitals, and expert organisations supporting innovators across the full innovation lifecycle. Eurobiomed bridges clinical and digital health strengths across two complementary regions: Région Sud (immunotherapies, dermatology, AI in health) and Occitanie (biotherapies, diagnostics, biomanufacturing). These ecosystems rely on strong collaboration between academia, healthcare providers, industry, and public authorities, supported by leading universities, hospitals, research infrastructures, and accelerators.

Cécile Rousselot
Head of Strategic Projects
cecile.rousselot@eurobiomed.org



France Biotech was founded in 1997 as an independent association, uniting the country's leading innovative health companies and their expert partners. As a key facilitator of the health innovation ecosystem and a privileged point-of-contact for public authorities in France and Europe, France Biotech helps address the major challenges facing the HealthTech sector (including company financing, innovation taxation, regulatory and market access issues, etc.). Its committees and working groups strive to identify viable solutions to create the necessary conditions for

THE FRENCH ECOSYSTEM

THE FRENCH ECOSYSTEM

a competitive and attractive industry. Its objective is to support HealthTech startups and SMEs in becoming successful international companies capable of designing and developing innovative products and solutions rapidly and ultimately making them accessible to patients.

Chloé Evans
Deputy Director General, Head of Market Research and International Relations
chloe.evans@france-biotech.org



France DeepTech is the biggest french deep tech hubs, driven by 2 missions. France DeepTech connect continuously our member through more than 40 initiatives per year, and develop business opportunities between its members, start-up, investors, laboratories, and corporates.

Romain Roulois
General Manager
romain.roulois@francedeepTech.org



Genopole has one of France's main incubators for biotech start-ups working in the fields of health, the environment or industry. Conceived and organized so that researchers and entrepreneurs can work and live together, Genopole attracts talent from around the globe.

Laurence Lacroix
Partnerships and Business Development Director
laurence.lacroix@genopole.fr



GenoTher is the first European biocluster exclusively dedicated to genetic medicine. It brings together key players from innovation, clinical research, and industry to accelerate the emergence and development of breakthrough therapeutic and technological solutions. Certified by the French government under the France 2030 plan, GenoTher provides access to cutting-edge platforms, contributes to training the next generation of talent, and supports the growth of high-potential companies.

Mélodie Dupré
Marketing and Partnerships
mdupre@genother.org



Lyonbiopole Auvergne-Rhône-Alpes is a French biocluster that connects and promotes healthcare innovation in Auvergne-Rhône-Alpes. Its mission is to support the development of innovative technologies, products, and services to address global healthcare challenges. With over 250 members, including world-class leaders, innovative SMEs, and research centers, Lyonbiopole fosters collaboration and development of breakthrough healthTech innovations to the benefit of patients.

Simon Gudin
Head of International Affairs
simon.gudin@lyonbiopole.com



MabDesign provides scientific, technological, and business expertise in biotherapies and bioprocessing, for the benefit of drug developers as well as service providers. Founded in 2014, self-financed and strong of over 380 French and European members, the MabDesign association is committed to being the leading expert resource for stakeholders in this highly innovative field.

Elsa Kress
Head of Business Development
elsa.kress@mabdesign.fr



WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y-Combinator, the company has established itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks. WhiteLab collaborates with major pharmaceutical companies (such as Sanofi), as well as leading academic institutions, and innovative biotech companies. WhiteLab is a member of the prestigious French Tech 2030 program and part of Bayer Co.Lab in Cambridge (USA).

Timothé Cynober
Global Head of Business Development and Licensing (BD&L)
tcynober@whitelabgx.com

Institutional Partners



AIS is the flagship measure of the "Innovation Santé 2030" program, and its role is to manage the implementation of the health component of France 2030 in conjunction with the relevant ministries and operators.

Clémentine Body
Director of Cross-Functional & International Projects
clementine.body@pm.gouv.fr



Our mission is to enable and empower businesses by providing them with crucial resources, including but not limited to an extensive network, advice on best business practices, market studies, potential client prospection and outreach, recruitment, implantation and more.

Sylvie Almeri
So-Cal FACC Managing Director
sylvie@france-socal.org



French Healthcare is an innovative public-private initiative aimed at bringing together all the players in the French healthcare ecosystem (businesses, researchers, healthcare professionals, key public stakeholders, etc.) to jointly promote their activities, expertise, technologies and innovations internationally. It helps to trigger a collective approach dynamic that stimulates international cooperation in the field of health and to promote the vision that health, a vector of social progress, must be improved for everyone everywhere in the world.

Julien Compiegne
French Healthcare Brand Manager
julien.compiegne@businessfrance.fr



La French Tech is a global movement uniting startups, investors, and policymakers to make France a premier hub for impactful innovation. Boasting a vast network worldwide, it stimulates local ecosystems to drive tech growth. The Southern California French American Chamber of Commerce is proud to establish La French Tech San Diego. This milestone reinforces the entrepreneurial bond between France and San Diego, fostering innovation, creating opportunities, and shaping a remarkable future for startups and tech companies in our vibrant city.

Sylvie Almeri
French Tech San Diego Managing Director
sylvie@france-socal.org





Cystic Fibrosis Rare diseases Respiratory

Aceso Therapeutics is an early-stage biotech company based in Montpellier focused on developing innovative therapies for cystic fibrosis, a rare and severe genetic disease that primarily affects the lungs.

The company's lead program, ACT-101, is a first-in-class inhaled antisense oligonucleotide (ASO) therapy. It introduces a novel upstream mechanism by increasing CFTR mRNA levels, leading to higher production of functional CFTR protein and improved channel activity. This differentiated approach is designed to complement and extend the benefits of existing treatments, both as a standalone therapy and in combination settings.

Supported by promising preclinical data, ACT-101 is advancing under regulatory guidance toward a planned IND submission by the end of 2027 to initiate Phase 1 clinical trials.

Thomas Tran

Chief Executive Officer

thomas.tran@aceso-therapeutics.com



Obesity Diabetes

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions for metabolic diseases, primarily diabetes and obesity. The company holds more than 25 patent families and is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

Adocia has a broad portfolio of drug candidates based on four proprietary technology platforms:

1. BioChaperone® for the stabilization and enhancement of peptide formulations and combinations
2. AdOral®, an oral peptide delivery technology
- 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation
- 4) AdoXLong™, a long-acting peptide platform

Jeremy Benattar

Head of Business Strategy

j.benattar@adocia.com



CNS Diseases Oncology IBD More

Affilogic is a private biotech company specializing in the discovery and development of affinity proteins, Nanofitins®, through early-stage collaborations with global pharmaceutical leaders.

Nanofitins® are hyperstable proteins, 20 times smaller than antibodies. They are easily combined by simple, rapid and proven methods to design an ideal targeted molecule.


Affilogic is internally advancing four programs leveraging the core advantages of Nanofitins®:

1. Bus2Brain: Enhancing brain uptake of biologics to reignite CNS therapies
2. Respitide: Inhaled antiviral Nanofitin® therapeutics for respiratory infections
3. GI Job: Targeting gastrointestinal diseases through oral administration
4. ODC: Small-size Nanofitin® drug conjugates for solid tumors with a new therapeutic window.

Olivier Kitten

Chief Executive Officer

olivier@affilogic.com



Gene therapy Oncology

Algenscribe is a pre-clinical stage biotechnology company developing a first-in-class Gene Replacement platform. The flexible platform aims to improve the efficiency and quality of Gene Editing from single bases to multi-kilobase replacements.

Algenscribe's platform tackles technological challenges in gene editing:


- 1) Boosts Efficiency: Dramatically increases gene replacement rates
- 2) Enhances Precision: Minimizes nuclease-induced mutations
- 3) Full-Scale Flexibility: Edits from single bases to multi-kilobase insertions
- 4) Versatile Utility: Spans therapeutics and bioproduction
- 5) Non-viral: Bypasses AAV-related delivery constraints.

Frédéric Zampatti

Chief Executive Officer

fredericzampatti@algenscribe.com





Oncology Colorectal Cancer Pancreatic Cancer

Antelope Therapeutics is a preclinical-stage oncology company developing ATL-024, an ADC with best-in-disease potential for the treatment of colorectal and pancreatic cancers, two diseases causing nearly 400,000 deaths annually across the 7MM.

Founded by ADC experts, former Mablink Bioscience executives, Antelope has identified CA242, a highly prevalent target across both tumor types that is absent from healthy tissues.

ATL-024 combines a clinically de-risked antibody, a proprietary linker platform, and a topoisomerase I inhibitor payload, and has demonstrated a compelling preclinical efficacy and outstanding NHP tolerability.

Targeting clinical entry in 2027, Antelope is seeking investors and strategic partners to accelerate the development of ATL-024.

Edouard Leroy
CEO & Co-founder
e.leroy@antelope-tx.com




Infectious diseases Antimicrobial Resistance Sepsis

AUROBAC THERAPEUTICS is a biopharmaceutical company established in 2022 through a strategic partnership between three global leaders in life sciences innovation: Boehringer Ingelheim, Evotec and bioMérieux. AUROBAC is dedicated to tackling urgent and unmet medical needs in the treatment of bacterial infections and their consequences in acute hospital settings, with a strong focus on the escalating threat of antimicrobial resistance (AMR).

AUROBAC is advancing a robust and diversified pipeline, headlined by ATX101, a potential first-in-class host-targeted therapy in development for the treatment of sepsis and septic shock (Phase 2 in preparation).

In parallel, AUROBAC has established multiple strategic partnerships to build a robust drug discovery engine designed to identify novel antimicrobial agents. This innovative platform aims to accelerate the development of novel treatments for acute respiratory infections.

Julie Cervesi
Chief Business Officer
julie.cervesi@aurobac-tx.com



Nephrology Metabolic diseases Urology

AVEROA PHARMA is a French "smart drug company" focused on the development and registration of therapies for patients with kidney and metabolic diseases. Averoa's expertise lies in building a strong pipeline of innovative products with the potential to address major unmet medical needs in nephrology and advancing them through development stages that maximize both therapeutic and commercial value.

The Averoa team has strong expertise in drug development through to full EMA and FDA approval, having successfully registered four products in the EU and US.

Averoa's first in-licensed, best-in-class product, Xoanacyl, received a Positive Opinion in 2025. Xoanacyl will be the only orally administered product with a unique dual mechanism of action, serving as a source of ferric iron while also reducing phosphorus absorption and directly lowering iFGF23 levels.

Luc Andre GRANIER
President & Founder
lagranier@averoa-pharma.com



Immuno-Oncology Inflammatory Diseases

Biomunex Pharmaceuticals is a clinical-stage biopharmaceutical company, focused on the discovery and development of breakthrough immunotherapies in oncology. Its proprietary BiXAb technology enables the rapid and cost-effective generation of bispecific and multispecific antibodies, based on strong IP. The platform has been validated through collaborations with pharmaceutical partners, such as Sanofi, Onward Therapeutics, and Ipsen. Biomunex is pioneering a novel immunotherapy approach that uses bispecific antibodies to specifically target and engage MAIT cells, a subpopulation of T cells, to kill cancer cells for the treatment of solid tumors, positioning the company at the forefront of disruptive innovation in cancer treatment.

Pierre-Emmanuel Gerard
Founder, President & CEO
pe.gerard@biomunex.com



Ophtalmology Retina Glaucoma

BIOPHTA's new standard of care offers a non-invasive, 7-day topical microdosing, to provide a continuous therapeutic exposure for replacing injections or daily eyedrops. This scalable platform offers a transformative solution to poor adherence, burden and pain of injections, as well as inconsistent outcomes.

Jean Garrec
CEO & Founder
jean.garrec@biophta.com




Immuno-oncology Solid tumors

BrenusPharma is a French clinical-stage biotech developing a new class of in vivo immunotherapies for solid tumors. Its proprietary, data-driven Stimulated-Ghost-Cell (SGC) platform transforms tumor complexity into scalable, off-the-shelf candidates by integrating multi-omics, predictive models, and GMP-ready manufacturing. It is designed to go beyond personalized therapies and address settings where current treatments fall short.

SGC technology reproduces tumor protein expression and makes these targets visible to the immune system, enabling broad, multi-specific responses against heterogeneous and evolving tumors.

The lead candidate, STC-1010, targets metastatic colorectal cancer and is currently in a Phase I/II trial (NCT06934538). Early data show favorable safety and initial immune engagement. Next milestones include U.S. IND submission, clinical readouts, and a Series B financing.

Léa Perles
Associate Director – Strategic Operations
lperles@brenus-pharma.com




Oncology Cell Therapy CAR-T

Collectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications.

With its in-house manufacturing capabilities, Collectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Collectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

Claire Roudot
Associate Director Business Development
claire.roudot@collectis.com



CNS Neurology Rare diseases

Ceres Brain Therapeutics is developing CBT101, a novel CNS therapeutic candidate targeting neuronal energy dysfunction in ALS and CTD, which is now entering Phase II clinical development.


CBT101 is being developed in amyotrophic lateral sclerosis (ALS), a rapidly progressive and fatal neurodegenerative disease with limited treatment options, as well as in creatine transporter deficiency (CTD), a rare paediatric neurological disorder with no effective disease modifying therapies.

The program is supported by robust non clinical data and early clinical evidence demonstrating central nervous system activity and target engagement in humans.

CBT101 is delivered as a non invasive nasal spray, offering a clear advantage in terms of patient convenience and treatment burden compared with injectable or hospital based therapies.

Thomas Joudinaud
Chief Executive Officer
thomas.joudinaud@ceres-brain.com





Market access Oncology Rare diseases Infectiology

Cevindra is a French pharmaceutical company providing integrated access solutions for innovative, essential, and niche medicines in France. Cevindra supports international biotech and pharmaceutical companies aiming to make their products available to French patients, especially in areas of high unmet medical need such as rare diseases, oncology, hematology, immunology, infectious diseases, and advanced therapies.

Cevindra combines early access, compassionate access, regulatory operations, pharmaceutical exploitation, hospital distribution, pharmacovigilance, quality oversight, data collection, and market access support. This model enables companies without a French affiliate or exploitant status to operate in France through a trusted local partner.

Cevindra supports innovative biotech companies from post-Phase 2b development onwards by helping them generate earlier revenue and provide French patients with access to the latest therapeutic innovations before full commercial launch.

Loïc Fievet

Business Development Director
l.fievet@cevidra.com




Otology Cognition Ageing

Cilcare is a clinical-stage biopharmaceutical company pioneering auditory science, developing innovative drugs and diagnostics to prevent and treat hearing disorders. Based in Montpellier, Paris, Boston and Tokyo, the company addresses a major unmet medical need worldwide: hearing loss, which is expected to affect nearly 2.5 billion people by 2050. Growing evidence identifies hearing loss as the leading modifiable risk factor for dementia. Through its integrated platform spanning therapeutic development, translational research, and AI-driven auditory analytics, Cilcare is committed to making hearing a global health priority and advancing precision medicine for patients worldwide.

Celia Belline

Chief Executive Officer
celia.belline@cilcare.com




Oncology mAb Development ADC Agrofood

Founded in 1995, Covalab is a leading French biotech specializing in antibody engineering, from polyclonal and monoclonal to scFv, Fab, VHH, and recombinant antibodies. Our DNA immunization technology excels at targeting conformational epitopes, including complex transmembrane receptors, enabling the development of high-affinity antibodies against TROP-2, PD-L1, Nectin-4, and more, available for ADC out-licensing.

With ISO 9001:2015 certification, we combine cutting-edge screening, characterization, and rigorous quality to deliver superior antibodies for research and therapy.

Saïd El Alaoui

Chief Executive Officer
elalaoui@covalab.com



Neurology Rare diseases

Based in France, Curlim is a biotech company developing therapeutic solutions for hereditary peripheral neuropathies and rare neurodegenerative diseases. These conditions, such as Charcot-Marie-Tooth disease (CMT) - the most common inherited peripheral neuropathy, affecting approximately 1 in 5,000 individuals worldwide - currently have no curative treatments.

Curlim has developed an innovative encapsulation platform that enhances solubility, stability, bioavailability, and intracellular penetration of bioactive molecules, enabling them to reach their full therapeutic potential. Preclinical results have been unprecedented: significant rescue of nerve function was demonstrated in two CMT1A animal models, with major improvements in Motor Nerve Conduction Velocities and normalisation of motor skills, with no signs of toxicity even after repeated doses. Beyond neuropathies, the platform is applicable to multiple drug candidates and therapeutic indications, making Curlim the owner of a scalable, high-value technology with strong long-term partnering and licensing potential.

Laurent Richebourg

Chief Executive Officer
laurent.richebourg@curlim.eu



Deepto

Advanced antibody expertise



Therapeutic proteins Antibodies Epitope mapping

Deepto supports therapeutic protein development through Epitope mapping, Paratope mapping and Optimization.

Epitope mapping: Data equally reliable whether the epitope is conformational or linear. In a short time frame (4 to 6 weeks).

Paratope mapping: In vitro functional data. Accurate to the nearest amino acid. Predictive of cross-reactivity & selectivity.

Optimization: A 360 screening, via the identification of all mutations of interest. Fast (4/6 weeks), definitive, comprehensive results.

Thanks to its services, Deepto helps clients optimize their development costs, by derisking their programs at the best cost/duration ratio:

- by obtaining an optimized lead ready for clinical trials
- via the reinforcement of the patentability (IP) of antibodies.

Fabien Quero

Co-founder - Admin & Business Development
fabien.quero@deepto.com

dolinnov



Chronic Pain Neuropathic pain Inflammatory Pain

Metastatic Cancer Pain

Dolinnov develops a first-in-class non-opioid therapy for chronic pain, addressing a major unmet medical need. Current approaches targeting ion channels show limited efficacy due to biological redundancy.

Dolinnov takes a differentiated approach by targeting a key regulator of neuronal excitability using lipid-ASO technology to selectively act at the dorsal root ganglion.

Its lead candidate, DOL-001, has demonstrated strong efficacy, long-lasting effects, and promising translational potential.


By targeting ion pumps rather than ion channels, Dolinnov offers a precise, peripheral alternative that avoids CNS toxicity and overcomes the limitations of existing pain therapies.

Grégoire Serra

Chief Executive Officer
gregoire.serra@dolinnov.com



Enemsa Pharma



Neurodegenerative Diseases Cardiopulmonary Diseases

Enemsa Pharma is developing first-in-class combination therapies for neurodegenerative and cardiopulmonary diseases driven by complex stress, inflammatory, and fibrotic mechanisms.

Its core asset, icerguastat, is an orally available, brain-penetrant small-molecule Integrated Stress Response (ISR) modulator with Phase 1 completed. Icerguastat acts as a versatile backbone for rapid "plug-and-play" combination development, targeting eIF2α signaling, NR2B-containing NMDARs, and mitochondrial oxidative stress. Enemsa's platform enables fast and synergistic pairing of icerguastat with standard-of-care therapies. Clinical validation includes a Phase 2 exploratory study of icerguastat + riluzole in bulbar-onset ALS showing favorable safety and biomarker signals.

Lead clinical program: icerguastat + riluzole in Amyotrophic Lateral Sclerosis (available for partnering).

Pierre Miniou

Chief Executive Officer
pminiou@enemsapharma.com



exeliom biosciences



Oncology Infectious diseases IBD

Exeliom Biosciences is a clinical-stage immunotherapy company developing a first-in-class oral innate immune modulator designed to enhance the efficacy and durability of immune checkpoint inhibitors (ICIs). Its lead asset, EXL01, selectively activates the non-canonical NOD2-CARD9 pathway, reprogramming tumor-associated macrophages to restore antigen presentation and strengthen T-cell-mediated anti-tumor responses. EXL01 is currently being evaluated in a randomized Phase II trial in first-line advanced gastric cancer in combination with nivolumab and chemotherapy. Additional expansion studies are ongoing in renal cell carcinoma, hepatocellular carcinoma, and NSCLC, across Europe and the United States. Beyond oncology, EXL01 is also being developed in Crohn's disease and in infectious diseases, where preliminary clinical efficacy signals have been observed. With a scalable GMP platform and patent protection through 2044, Exeliom Biosciences offers a differentiated strategy to enhance and extend ICI-based therapies.

Benjamin Hadida

Chief Executive Officer
bhadida@exeliombio.com



H.A.C-Pharma



Neurology Onco-hematology Endocrinology

Rare diseases

H.A.C. Pharma offers unique end-to-end capabilities for launching high-therapeutic value medicines across Europe, particularly in conditions with limited treatment alternatives. By managing all key functions internally, including regulatory affairs, market access, medical science liaison, pharmacovigilance, medical information, and commercial activities, H.A.C. Pharma ensures timely implementation, agility and quality.

H.A.C. Pharma in-house regulatory team can manage European registration through various procedures, including orphan designation, centralized procedures and early access programs.

François Huguet

Head Strategy and Business Development
francois.huguet@hacpharma.com



Oncology CNS Brain Tumor More


HEMERION Therapeutics is a clinical-stage healthcare company focused on the discovery and development of innovative therapies that combine photosensitizing molecules and laser light technologies. This combination product strategy is aimed at the selective treatment of resistant tumors.

The product combination integrates seamlessly into the surgical workflow and destroys tumor cells without harming healthy cells, leading to more favorable disease outcomes with longer progression-free survival (PFS) and overall survival (OS).

With two successful clinical trials already completed in France, Hemerion is sponsoring a new clinical trial in the U.S. after receiving IND approval from the FDA in 2023.

Maximilien Vermandel

Chief Executive Officer
mv@hemerion.com



Oncology

HEPHAISTOS is a preclinical stage biotech developing a 3rd generation innate immune activator.

The objective is to offer an option to optimize responses to current immunotherapies by overcoming myeloid-driven tumor immunosuppression.

HEPHA-440, boosts antitumor efficacy by: recruiting immune-effector cells into the TME, reverting macrophage polarization, activating dendritic cells and antigen presentation, and triggering CD8 T-cell-mediated cytotoxicity

HEPHA-440, has demonstrated: 30x to 400x better safety and 2x better efficacy compared to previous generation in clinical phases, single agent efficacy with complete tumor regressions and systemic effect against metastases, synergies with aPD1 and aCD20 antibodies with up to 100% complete tumor regressions.

Frédéric Caroff

Chief Executive Officer
fc@hephaistos-pharma.com



Infertility

Igyxos is a French biotechnology company dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. Igyxos' lead asset is IGX12, a first-in-class humanized monoclonal antibody which is Phase 2 ready.

Florent Ferré

Chief Executive Officer
florent.ferre@igyxos.com





Oncology Vaccine Innovative therapy

InSpek is a French deep tech company that is redefining bioprocess development and manufacturing by using multiparametric real-time monitoring and AI. Its bioprocess optimization platform not only analyzes data, but also collects it thanks to its proprietary photonic sensing technology, which was developed at MIT and CNRS. InSpek's multi-parameter monitoring system, MultiSpek, integrates Raman spectroscopy, pH, dissolved oxygen, temperature, and optical density sensing on a single, reusable microchip. When paired with a reusable control unit and AI-driven software, the system provides continuous, in-line monitoring of critical process parameters directly within bioreactors, replacing slow and costly offline sampling methods. Designed for both single-use and stainless steel bioreactors of all sizes, InSpek enables pharmaceutical, biotech, manufacturers to optimize yields, reduce batch failures, and accelerate scaling up toward smart, data-centric biomanufacturing 4.0.

Tifenn Naour

Chief of Staff

tifenn@inspek-solutions.com



Oncology

Kahimmune is a next generation biotech company pioneering the re exploration of the cancer immunoepitome to develop synergistic, mRNA-based companion neoantigen therapies (CNT). By deeply mining the "dark genome" through its innovative proprietary platform, Kahinomics™, Kahimmune uncovers novel neoantigens designed to power innovative combination strategies in oncology.

Philippe Villain-Guillot

Chief Executive Officer

pvg@kahimmune.com



Neurology CNS Blood-brain Barrier Neuroinflammation


Lys Therapeutics' lead drug candidate, LYS241, is a first-in-class, fully humanized IgG1 monoclonal antibody designed to address a central and previously untargeted mechanism shared across multiple neurological disorders. By acting upstream of neuroinflammation, excitotoxicity, and blood-brain barrier (BBB) disruption, LYS241 targets a core pathological axis common to acute and chronic neurodegenerative diseases. Mechanistically, LYS241 selectively prevents the interaction between tissue plasminogen activator (tPA) and NMDAR, without altering the physiological function of NMDAR.

As a result, LYS241 restores BBB integrity, protects both vascular and neural compartments, and promotes a return to tissue homeostasis. This dual vascular and neuroprotective activity positions LYS241 as a differentiated therapeutic approach capable of modifying disease biology rather than merely alleviating symptoms. By targeting a unifying upstream mechanism, Lys Therapeutics is advancing a pipeline-in-a-drug strategy with the potential to impact a broad spectrum of neurological diseases driven by neurovascular dysfunction and inflammation.

Manuel Blanc

CEO & Co-Founder

mblanc@lystherapeutics.com



Oncology Antibodies ADC

MABQI is a biotechnology company specializing in next-generation antibodies and immunotherapies. Its proprietary LiteMab® Antibody Discovery Studio integrates synthetic fully human antibody libraries with an AI-powered dual-display platform, enabling precise identification of highly developable leads.

The innovative LiteMab Sense platform enables the discovery or maturation of pH-sensitive binders that activate selectively in tumor or acidic microenvironments, enhancing therapeutic safety and efficacy.

MABQI is advancing a targeted oncology pipeline of first-in-class and best-in-class candidates—some featuring pH-sensitivity—across antibody-drug conjugates (ADCs), multispecific antibodies, and TCE to address high unmet needs.


Sylvain Yon

Chief Executive Officer

sylvain.yon@mabqi.com



medincell.



CNS [More](#)

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments that improve adherence, broaden access to care, and reduce environmental impact. Its products use Medincell's proprietary BEPO® and BEPO® Star technologies, enabling controlled drug release for days to months from a small, fully bioresorbable injection.

The first BEPO®-based therapy, risperidone LAI, received FDA approval for schizophrenia in 2023 and Bipolar I Disorder in 2025, and is marketed in the U.S. as UZEDY® by Teva. It was also approved in Canada and South Korea in 2025. Teva's NDA for once-monthly olanzapine LAI was accepted by the FDA in February 2026.


Medincell's pipeline spans formulation to Phase III programs, supported by global partnerships. The company is headquartered in Montpellier and employs over 140 people.

Sébastien Enault

Chief Business Officer

sebastien.enault@medincell.com

NETRIS Pharma



Oncology [Endometriosis](#) [Fibrosis](#)

Netris Pharma is a clinical-stage company developing innovative therapeutics to improve treatment outcomes for cancer patients and overcome resistance to chemo- and immunotherapies.

Its lead asset, NP137, is a first-in-class monoclonal antibody targeting Netrin1, a novel and untapped oncology target aberrantly expressed in multiple tumor types. NP137 has demonstrated an excellent safety profile both in monotherapy and in combination therapies, as well as promising antitumor efficacy in solid tumors such as pancreatic and head and neck cancers.

The company is also investigating the unique mechanism of action of NP137 to develop the first non-hormonal disease-modifying agent for the treatment of endometriosis. Netris Pharma has generated exciting preclinical data demonstrating reductions in disease progression, inflammation, fibrosis and related pain symptoms.

Patrick Mehlen

Chief Executive Officer

patrickmehlen@netrispharma.com



france
biotech



LYONBIOPOLE
AUVERGNE-RHÔNE-ALPES
THE HEALTH INNOVATION NETWORK

NFL
Biosciences



Neurology [Addictions](#)

NFL Biosciences is a Phase 3 French publicly listed biotech company (ticker: ALNFL), developing NFL-101 and NFL-102, disruptive drug candidates for smoking cessation with a new and distinctive mechanism of action.

NFL-101 has recently completed a randomized, doubleblind, placebo-controlled Phase 2b trial (3 arms: 2 doses and placebo; n=318 patients) with a 12-month followup. The treatment involves two subcutaneous injections administered one week apart, optimizing both compliance and efficacy. NFL Biosciences has been able to show superiority of NFL-101 vs placebo, with an efficacy similar to Champix, the gold standard in smoking cessation therapy. Unlike Champix, NFL-101 shows no serious side effects and has a convenient dosing schedule.

NFL-102 is now entering a Phase 2b study.

Ignacio Faus

Managing Director

ifaus@nflbiosciences.com



france
biotech

nicox
visible science



Ophthalmology

Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.

The lead program of Nicox's ophthalmic pipeline, NCX 470, has successfully completed Phase III clinical development targeting glaucoma in the U.S. and China, with a separate Phase III program ongoing in Japan. Our ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728.

Nicox has two products which are commercialized in the U.S.; VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIAE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis respectively. ZERVIAE is also commercialized in China.

Emmet Purtil

Vice President Business Development

purtil@nicox.com

france
biotech

EUROBIOMED



Oncology Parkinson's disease Inflammatory

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine.

OPM currently has two kinase inhibitors preparing for Phase 2 clinical phases in patients: OPM-101, a RIPK2 inhibitor is ready to start a Phase 1b/2a in few months aiming at reverting resistance in advanced melanoma patients not/no longer responding to PD1 checkpoint inhibitors. OPM-201, a LRRK2 inhibitor for Parkinson's disease prepares for a Phase 1b/2 study in patients with LRRK2 genetic variants Q1 2027. Ongoing CMC and toxicology work is fully funded by a grant award from the Michael J Fox Foundation, representing a major validation of the compound by the best experts.

Both molecules come from the Nanocyclix® medicinal chemistry platform, which enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors. The platform is AI assisted and consists of a highly annotated database and over 12,000 molecules.


Jan Hoflack
Chief Scientific Officer
jhoflack@oncodesign.com



Oncology Vaccines

Oncovita is a spin-off of the Institut Pasteur that develops immuno-virotherapies for solid cancers, based on a genetically modified measles vaccine virus. Its main candidate, MVdeltaC, is an oncolytic virus capable of inducing immunogenic cell death and has shown promising preclinical results in many models, including immunocompetent mouse models. This virus specifically targets tumor cells overexpressing the CD46 receptor and induces a durable antitumor immune response.

Stéphane Altaba
Chief Executive Officer
stephane.altaba@oncovita.fr



Oncology Immunology Inflammatory

OSE Immunotherapeutics is an integrated Clinical Stage biotech company mastering complex biology with regards to T-cells and myeloid cells, focused on developing first-in-class assets targeting immuno-oncology, autoimmune and inflammatory diseases.

OSE Immunotherapeutics has a dynamic partnership business model based on innovative products that generates non-dilutive revenues and finances R&D programs. These products have real blockbuster potential, enabling OSE-Immunotherapeutics to secure global agreements at various stages of development with major pharmaceutical players.

The company is open to discussing potential collaborations and is actively seeking international partners for the out-licensing of compounds at all stages of clinical development.

Romain Gret
Director of Business Development
romain.gret@ose-immuno.com



Neurodegenerative Diseases Metabolic diseases

SITERA Pharmaceuticals is a biotech company dedicated to developing innovative therapies for rare and less rare neurodegenerative diseases with urgent and unmet medical needs. Its dedication is to provide clinical solutions to improve patient life conditions who have reached therapeutic impasse.

By leveraging its proprietary technology platform, which combines cutting-edge chemical and biological expertise, SITERA design powerful, selective, and safe small molecule therapeutics. The company is thus able to adress challenging central nervous system diseases and potentially provide benefit for patients.

Henri Piras
Chief Executive Officer
henri.piras@siterapharma.com





Skin protection Skin cancer prevention

Skinosive is a science-based biotechnology company specializing in dermocosmetics, founded by Truffle Capital, which is developing a proprietary technology platform called "bioadhesion" that could be applied to several use (cosmetic, medical...).

Skin cancer is the leading cause of cancer among Caucasians. The best means of prevention remains sun protection, but this has two major limitations: its effectiveness, as it must be reapplied every two hours, and the issue of skin penetration.

Skinosive is the only company developing an innovation based on a new generation of safe, long-acting bioadhesive filters. This breakthrough represents a radical innovation in sun protection and skin cancer prevention.

Agnès Menut
Business Development Director
agnes.menut@skinosive.com




Respiratory Drug delivery

Despite a growing number of approved monoclonal antibodies targeting respiratory diseases, none are delivered by inhalation - nebulization damages antibodies and no validated solution currently exists. SoteriaBio is a French pre-clinical biotech developing a proprietary technology platform to solve this.

Backed by \$4M in seed funding and grants, SoteriaBio has demonstrated in vivo proof of concept showing complete lung distribution, higher local concentration versus systemic injection, and therapeutic efficacy in preclinical asthma and COVID models. Led by Anh Nguyen, founder of MedinCell (EURONEXT: MEDCL), SoteriaBio operates in Montpellier (France) and Montreux (Switzerland).

Lionel Brodard
Chief Financial Officer
lionel.brodard@soteria.bio



Oncology

Syndivia is focused on unlocking the full therapeutic potential of antibody-drug conjugates by restoring the antibody as an active driver of efficacy, rather than treating it as a passive payload carrier. GeminiMab ADC platform allows conjugation while preserving antibody exposure close to that of the unconjugated backbone, enabling dosing levels where antibody biology is fully expressed.

Sasha Koniev
Chief Executive Officer
ok@syndivia.com



Ophthalmology

Théa Open Innovation (TOI) is the external innovation unit of Laboratoires Théa, a family-owned, independent company fully dedicated to ophthalmology, operating in 75 countries including North America. Its mission is to identify and support the most promising developments in eye care, regardless of technology, mainly through licensing agreements.

TOI provides:

- Funding to reach human proof of concept
- Deep expertise in clinical development, regulatory approval, market access, and commercialization
- A collaborative model where partners retain full control of their project

TOI is actively seeking collaborations with startups, investors, incubators, and academic teams working in the ophthalmology field. Its focus is on projects that have a lead asset or prototype and early efficacy data (e.g., proof of concept in animal models), and are looking for an industrial partner to accelerate their development.

Antoine Joyaux
Business Development Manager
antoine.joyaux@theaopeninnovation.com





Neurology Rare diseases

THX Pharma (Euronext Growth: ALTHX) is a clinical-stage, patient-focused rare-disease company transitioning from biotech to commercial pharmaceutical model.

Focus: orphan CNS/lysosomal disorders with rare-disease formulations and rapid regulatory paths. Break-even targeted 2028. THX Pharma has two lead assets TX01 and Batten-1.

TX01 is a proprietary, high-concentration oral solution built on an approved active ingredient, specifically formulated to address specific unmet needs in two rare lysosomal storage disorders: Niemann-Pick disease type C and Gaucher disease. THX retains APAC rights and is actively seeking out-licensing partners to complete its global coverage.

Beyond its clinical-stage assets, THX Pharma can leverage a proprietary discovery platform to identify and develop next-generation drug candidates based on antisense oligonucleotide (ASO) technology.

Julien Veys

Chief Operating Officer

julien.veys@thxpharma.com



Oncology CNS Skeletal and Cardiac Muscles

Vect-Horus designs and develops vectors (peptide or small antibody-based) that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain, muscle tissue and some tumors.

The VECTrans® technology exploits specific receptors selected for their high uptake/endocytosis and constitutive recycling capacity, thereby allowing significant intracellular transport and accumulation of therapeutic or imaging agents.


Once the vector moiety of a vector-payload complex is locked onto the appropriate receptor at the surface of BBB endothelial cells, cancer cells or any target cell type expressing such receptors, the vector-payload complex undergoes rapid internalisation and subsequent intra/transcellular trafficking.

This ultimately leads to payload delivery into cells and across the BBB into the brain via transport and transcytosis processes respectively thus modifying pharmacokinetic (PK) and distribution profile of therapeutic or imaging candidates.

Faustine Velasco

Senior Business Developer

faustine.velasco@vect-horus.com



TPD Small Molecules Molecular glues More

ALPX, an EMBL spin-off, specializes in transparent structural biology services for biotech and pharma companies. The company delivers rapid, high-quality, structural insights, enabling partners to focus on optimizing small molecule and biologic programs into lead candidates. Through its automated protein crystallography and cryo-EM platforms, ALPX provides a one-stop solution for structural biology needs.


The Automated Protein Crystallography platform is centred around two key proprietary technologies, CRIMS and CrystalDirect™, designed to streamline and automate protein crystallization. Combined with weekly access to synchrotron facilities and an efficient processing pipeline, the platform enables a rapid turnaround from compound delivery to structure determination.

The Cryo-EM platform features an integrated workflow from grid preparation and screening to data collection and structure determination, supported by access to leading imaging centers and robust cloud-based processing solutions.

Alexandre Dias

Head of Business Development

dias@alpx-services.com



Oncology Immunology

Antineo is a CRO specializing in preclinical proof-of-concept studies for anticancer agents. Its activity focuses on the evaluation of new anticancer compounds (small molecules, antibodies, peptides, etc.). The company provides scientific consulting and supports clients in optimizing the development of anticancer candidates through a range of services covering in vitro assays (cell toxicity, sample characterization), ex vivo analyses (mechanism of action or target identification by flow cytometry), and in vivo studies (antitumor efficacy, toxicity, pharmacokinetics).

Antineo's services are delivered by a team with internationally recognized expertise in onco-pharmacology. The company works with French and international organizations, ranging from academic researchers (through technology transfer structures such as SATTs), to small and medium-size biotech companies, and large pharmaceutical companies. Antineo has conducted over 300 preclinical studies for more than 150 clients since its creation.

Marie Tautou

Study Director & Head of Business Development

marie.tautou@antineo.fr



Astrum



Oncology Immunology CNS

Astrum is a global CRO delivering full-service clinical development to biotech companies. With a team of over 250 professionals, it combines large-CRO scientific capabilities with mid-size agility, offering faster execution timelines and direct access to decision-makers. The company supports programs from first-in-human studies through Phase III across oncology, immunology, and CNS indications.

Astrum operates a proprietary 64-bed Phase I clinical unit in Portugal (EMA/FDA/ANVISA-inspected), enabling early-phase studies including single and multiple ascending dose, drug-drug interaction, bioequivalence, and food-effect trials in healthy volunteers and patients, including critical indications through its integrated intensive care unit.

Headquartered in Europe, with large operational coverage and a decade-long US partnership, Astrum provides the geographic reach biotech sponsors require for international clinical programs. The company also holds CIR accreditation in France, enabling sponsors to benefit from meaningful R&D tax incentives.


Elisabeth Lackner

Chief Executive Officer

elisabeth.lackner@astrumcro.com

france
biotech

Atlantic Bone Screen



Osteoarticular Inflammatory Oncology More

Atlantic Bone Screen is a specialized preclinical CRO with recognized expertise in bone and joint health, as well as oncology.

The company provides both in vitro and in vivo non-GLP evaluation of drug candidates, supporting the demonstration of product efficacy compared with standard of care or competitor products.

Atlantic Bone Screen's capabilities include:

- In vitro models using tumor cell lines, macrophages, chondrocytes, osteoblasts and osteoclasts, as well as keratinocytes, fibroblasts, and skin explants
- In vivo models in rats and mice, including both chemically and surgically induced pathologies, supported by its in-house animal facility

Arnaud Guegantou

Business Developer

arnaud.guegantou@atlantic-bone-screen.com

ATLANPOLE
biotherapies
Thinking up tomorrow's medicine

cenexi

creating innovative partnerships



Oncology Immunology Rare diseases

CENEXI is a leading CDMO in Europe for drug products, specializing in compounding, fill and finish of injectables (vials, lyophilized products, pre-filled syringes and ampoules), as well as hormonal and desensitizing tablets. Cenexi provides industrial development and scale-up for commercial products, as well as clinical batches for Phases I, II, and III.

Drug substances compounded and filled include biologics, vaccines, mAbs, ADCs, high-potency compounds, sex hormones, and conventional products.

Christine Adam

Director of Business Development

christine.adam@cenexi.com

Chelatec



Oncology

Chelatec offers preclinical research services dedicated to the development of therapeutic radiopharmaceuticals in oncology.

With state-of-the-art laboratories fully equipped for radiochemistry, radioanalyses, cell handling and animal housing, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo/ex vivo investigation capabilities.

Backed by 25 years of expertise in dedicated laboratories, Chelatec provides partners with the data required to support their Investigational Medicinal Product documentation package, including the quality and non-clinical safety data necessary for the translation of a radiopharmaceutical into clinical development.

Julien Le Gal

Business Development Manager

julien.legal@chelatec.com

ATLANPOLE
biotherapies
Thinking up tomorrow's medicine




Muscle Kidney Cardiology

CYTOO specializes in micropatterned cell culture substrates and cell-based assay services for pharmaceutical drug discovery. Its proprietary micropatterning platform bridges standard 2D cultures and 3D organoids, combining physiological relevance with the standardization and throughput required for high-content screening. The company's flagship platform, Myoscreen, models primary human skeletal muscle at scale and supports a mature, validated assay portfolio covering atrophy, hypertrophy, mitochondrial network morphology, ROS quantification, lipid accumulation, and an FDA-validated DMD potency assay. Services are delivered as fully analyzed data packages within four to six weeks, supported by its internal Data Science team. Beyond skeletal muscle, CYTOO is expanding its portfolio with cardiac, kidney proximal tubule, and smooth muscle platforms. A licensing model for the Myoscreen platform is also being developed for large pharmaceutical companies seeking in-house implementation of validated workflows.

Elie El Hachem

Business Development Director
eelhachem@cytoo.com



Metabolic diseases Obesity Skin disorders [More](#)

DIVA Expertise is the leading global scientific partner for companies in the health, nutraceutical, and cosmetics industries seeking to evaluate the efficacy of active ingredients and products directly on human adipose and skin tissues, both ex vivo and in vitro.

The company offers turnkey R&D projects using unique, scientifically validated predictive human biological models to provide industrial partners with robust mechanistic evidence that accelerates and ensures the safe market launch of innovations in cosmetics, nutraceuticals, and metabolic and obesity-related therapeutics.

What sets DIVA apart is its biobank offering and innovative in vitro and ex vivo models. By leveraging biological materials from human donors and adhering to the 3Rs principles (reduction of animal testing), the company provides preclinical expertise closely aligned with human adipose tissue physiology.

Sandra Robelet

Business Developer
sandra.robelet@diva-expertise.com



Neurology Dermatology Cardiology

ETAP-LAB is an independent preclinical CRO providing efficacy testing and pharmacology services to pharmaceutical, biotechnology and medtech companies. With more than 35 years of expertise, ETAP-LAB offers four centers of excellence:

- BrainXplore: neurology and psychopharmacology
- Stro@lliance: ischemic and hemorrhagic stroke models
- SkinAxis: dermatology including both inflammation models and wound healing
- SynCROsome: cardiology

ETAP-Lab also provides a wide range of models and tools related to inflammation and fibrosis. Its services support drug discovery programs from in vitro lead optimization to non-GLP animal testing, to evaluate the efficacy of drug candidates and medical devices. ETAP-Lab relies on state-of-the-art facilities and equipment, including high-content imaging, in vivo imaging platforms, microsurgery capabilities, as well as comprehensive immunohistochemistry and bioassay readouts.

Nicolas Violle

Chief Executive Officer
nviolle@etap-lab.com



CNS Cardiology Oncology [More](#)


Eurofins Optimed is a French full-service CRO and Clinical Pharmacology Unit specialized in early-phase clinical development within the Eurofins Group. With more than 35 years of experience, the company supports pharmaceutical, biotechnology and medical device developers in the design, execution and management of Phase I and Phase II clinical trials in healthy volunteers and patients. Operating from its dedicated clinical facility, Eurofins Optimed combines scientific rigor, regulatory expertise and operational excellence to accelerate the transition from preclinical research to clinical proof of concept.

This expertise is now further strengthened by the French Fast Track regulatory framework, which can enable authorization within 14 days in eligible cases. Close collaboration with sponsors, investigators and regulatory authorities contributes to efficient study initiation and execution.

Capucine Henquell

Sales & Contract Manager
capucine.henquell@ba.eurofinseu.com





Neurology Oncology [More](#)

Firalis Molecular Precision (FMP) is a CAP-accredited, GCLP-compliant CRO specializing in translational multi-omic biomarker solutions for pharma and biotech companies. Beyond data generation, FMP integrates genomic, proteomic, and transcriptomic data with clinical context to deliver actionable insights across the full drug development continuum, from target discovery and biomarker R&D to clinical trial testing.

As an Olink-certified laboratory, FMP is uniquely positioned to provide protein biomarker profiling at scale. With over 15 years of experience and 100+ clients worldwide, Firalis Molecular Precision is the strategic partner of choice for organizations seeking to build a robust biomarker strategy and advance their pipeline with confidence.

Sidzigui Christelle Ouedraogo
Business Developer
christelle.ouedraogo@firalis.com



Ophthalmology

More than an ophthalmology-focused CRO, Iris Pharma supports clients worldwide at every stage of drug and device development. The company delivers customized solutions by assessing potential therapeutic effects in ocular diseases, adding value to promising drug candidates and medical devices, and designing development plans, preclinical packages, and studies to support further development.

From preclinical development services to innovative technology platforms and techniques, IRIS Pharma has built extensive expertise across all ophthalmic indications, supported by:

- 70 FDA, PMDA, and EMA ocular drug approvals and ophthalmic medical device marketing authorizations
- State-of-the-art medical and scientific equipment
- Highly specialized and qualified staff
- CIR agreement

Yann Quentric
Chief Executive Officer
y.quentric@iris-pharma.com



Immunology Rare Diseases Haemostasis Intensive Care

In the complex world of biomanufacturing, technical precision is the standard, but human commitment is the difference. LFB Biomanufacturing understands that a biological breakthrough is more than a formula or a process: it is a promise waiting to be kept.

LFB Biomanufacturing is the human link between science and patient's story. The company knows that moving a molecule from the lab to the real world requires more than just high-end equipment. It requires dedicated expertise that turns biological breakthroughs into a patient's reality.

When you partner with LFB Biomanufacturing, you are not just accessing a facility; you are connecting with a team that takes ownership of your vision. LFB Biomanufacturing is the bridge that ensures innovation doesn't just stay in a vial, but becomes the next chapter in a person's life. LFB Biomanufacturing: The human link between your science and their story.

Vincent Dehousse
Chief Business Officer
vincent.dehousse@lfb.fr




Neurodegenerative Diseases Rare Diseases CNS [More](#)

Motac Neuroscience, with operations in Bordeaux (France) and Beijing (China), is a CRO specialized in preclinical research for neurological and neurodegenerative disorders. Motac Neuroscience supports biotechnology and pharmaceutical companies by generating robust and translationally relevant preclinical data to advance therapeutic candidates toward clinical development.

Motac Neuroscience provides integrated platforms combining rodent and non-human primate models with behavioral assessments, in vivo imaging, biomarker analysis and histopathological endpoints. These multidisciplinary approaches generate comprehensive datasets that support critical decision-making from proof-of-concept to IND-enabling studies.

Erwan Bezard
CEO & CSO
e.bezard@motac.com



Rare diseases Alzheimer's Parkinson's ALS

Neuron Experts has deep expertise in neuronal cell culture, with strong know-how in reproducing disease-relevant stress mechanisms that mimic neurodegenerative conditions in vitro. The company induces pathological processes such as protein aggregation, oxidative stress, and mitochondrial dysfunction, enabling the development of highly predictive and physiologically relevant models.

In addition, Neuron Experts has advanced capabilities in high-content imaging and quantitative image analysis, allowing precise, multiparametric evaluation of the neuroprotective effects of compounds. These robust and sensitive platforms provide clients with reliable tools to assess efficacy across multiple neurodegenerative indications.

These in vitro models are highly complementary to the in vivo approaches developed by Motac, offering a comprehensive and translational preclinical strategy for drug development.

Remy Steinschneider

CEO & Head of Neuropharmacology
remy.steinschneider@neuronexperts.com



Oncology Kidney Immunology More

From early discovery to candidate selection, Novalix tailors every project around clients' needs and goals. Engagements are driven by experienced scientists using advanced technology to increase the odds of success at each stage.

Comprehensive capabilities are organized across five centers of excellence: Chemistry, Biophysics, Pharmacology and DMPK, Drug Discovery, and Cosmetics.

A wide range of expertise is covered, including medicinal chemistry, cheminformatics, synthetic chemistry, process chemistry and scale-up, biophysics, protein production with a focus on GPCRs, and structural biology techniques. Novalix also excels in in vitro and in vivo pharmacology, translational science, biobanking, histology, ADME-DMPK, and pre-formulation. Scientific expertise includes diverse modalities, such as small molecules, biologics, and PROTACs. State-of-the-art facilities are located in France and Tunisia, with business representative offices in the United States and Japan, ensuring a global presence and reach.

Denis Zeyer

Chief Executive Officer
dzeyer@novalix.com



Oncology Inflammatory Infectious diseases

Oxeltis has built a preclinical R&D consortium dedicated to supporting biotech start-ups in Europe and the United States in advancing early-stage drug discovery programs.

The company provides rapid hit-to-lead and lead optimization services through highly skilled team of chemists, alongside expertise in complex and enabling chemistries. Its advanced hybrid SFC platform enables efficient purification and scale-up of chiral and achiral compounds. Oxeltis also offers integrated biological services, including assay design, in vitro screening, and early pharmacology profiling, accelerating DMTA cycles and decision-making.

Through a flexible hybrid model combining European expertise with selected Asian CROs, Oxeltis ensures faster, cost-effective progression from hit to preclinical candidate without compromising quality or IP control.

Christophe Parsy

Business & Strategic Development Director
parsy.christophe@oxeltis.com



Oncology Rare diseases Immunology


Phinc. Modeling is a Contract Research Organization (CRO) specialized in Quantitative Pharmacology Solutions to support biotech in the development of drug candidates, new chemical and biological entities.

By using mathematical models and simulations, we can anticipate the effects of a drug candidate in different populations and conditions, thereby reducing risks and costs associated with clinical development. Through MIDD, we aim to improve the efficiency of clinical trials and accelerate the market entry of new treatments.

Samia Ezzine

Chief Scientific Officer
sezzine@phinc-modeling.com





CNS Pain Inflammatory Metabolism disorders
Obesity [More](#)

Porsolt is a Center of Excellence in non-clinical pharmacology with over 40 years of experience delivering high-quality research services to the pharmaceutical, biotechnology, and academic sectors. Renowned for its scientific expertise and innovation, Porsolt offers a comprehensive portfolio of services spanning safety and efficacy pharmacology, toxicology, histology, PK/PD, and biomarkers assessment, helping clients advance their drug discovery and development programs efficiently and effectively.

Porsolt's commitment to excellence is reflected in its adherence to global regulatory standards, including GLP compliance and AAALAC certification, ensuring that all studies meet the rigorous requirements of regulatory agencies worldwide. Its advanced histology capabilities play a pivotal role in this process, offering unparalleled insights into tissue morphology and pathology.

David Pushett

Director Global Business Development
dpushett@porsolt.com



Dermatology Immunology Inflammatory Oncology

QIMA Life Sciences empowers global leaders in pharmaceutical, biotech, and cosmetic industries with science-driven, predictive preclinical and clinical models and evaluations. Their solutions accelerate development, enhance success rates, and optimize resources by identifying the most promising candidates or active ingredients early in the pipeline. With deep scientific expertise, they serve as a trusted partner—delivering robust data that strengthens decision-making and fuels innovation at every stage of product development—because better science leads to better lives.

Luis Jimenez

Head of Pharma
luis.jimenez@qima.com



cGMP Chemistry Analytical


Roowin is a privately owned and agile CRO headquartered in France. Specializing in complex chemistry, the company provides a comprehensive suite of chemical and analytical services designed to accelerate drug development journey.

From early drug discovery through process development, Roowin partners with clients to advance small molecule candidates through IND/IMP submission and beyond, including Phase II API licensing and small-scale commercial production (up to ~20 kg).

With almost 30 years of experience, more than 100 molecules advanced to the clinic, and a track record of producing first batches for dozens of startups, some now valued at several billion on the stock market, Roowin demonstrates an exceptionally strong proven record.

Patrice Roel

Chief Executive Officer
patrice.roel@roowin.fr



All therapeutic areas

SEQENS is a global leader in the pharmaceutical industry, with over 30 years of experience in the development and manufacturing of APIs, intermediates and polymers.

Seqens' state-of-the-art R&D facilities in Europe and the US, along with its network of eight manufacturing sites (GMP and non-GMP), enable the company to innovate, develop and industrialize the most demanding molecules while implementing the best available technologies.

The company supports its customers from early-stage development to commercial production, offering tailored solutions for complex molecules.

As a trusted partner to over 1,000 customers worldwide, Seqens is backed by a strong CMC project management team, offering the highest level of service and commitment.

Oscar Rebolledo

Business Development Manager
oscar.rebolledo@seqens.com



Neurodegenerative diseases Alzheimer's Parkinson's

AgentT's innovative solutions are built around HORIZON™, a proprietary multiomic platform designed to predict and monitor neurodegenerative diseases through a simple blood sample.

HORIZON™ combines patented biomarkers, targeted mass spectrometry, and AI-based software, and can monitor 8 key biological pathways through 85 biomarkers. Its first applications, B-HEALED™ and B-AHEAD™, are blood-based tests designed to predict progression to Alzheimer's dementia symptoms in cognitively unimpaired and impaired individuals.

These products have already shown strong performance in a first multicenter retrospective study involving 632 individuals across the US, Europe, and Australia, with 3x fewer false positives than current tests on the market. AgentT is now advancing these solutions through an ongoing 4,200-participant pivotal clinical validation study.


Baptiste Billoir

Co-founder

baptiste.billoir@agent-biotech.com



AQEMIA



Oncology Neurology CNS

AQEMIA is a drug invention company developing novel molecules to address unmet medical needs. Its proprietary QEMI platform combines over a decade of physics-based research with state-of-the-art generative AI, enabling the rapid design of drug candidates without relying on experimental training data.

By leveraging its unique fast physics engine, the company reconciles speed and precision in molecular design, unlocking large-scale exploration of previously inaccessible chemical space. Aqemia's portfolio spans oncology, immunology and neurology, and includes both wholly owned programs and partnered programs with leading pharmaceutical companies, such as a multi-year, \$150M strategic collaboration with Sanofi.

The company's most advanced preclinical programs are currently undergoing in vivo optimization, demonstrating superior efficacy in animal models.

Maximilien Levesque

Chief Executive Officer

maximilien.levesque@aqemia.com



BIOHIVE

Innovations



Dermatology Rare genetic disorders Inflammatory

BioHive is a biotech company advancing pharmaceutical and cosmetic innovation through next-generation human skin models. BioHive develops 3D skin organoids, reconstructed tissues, and patient-derived platforms that better replicate human biology than conventional preclinical models. Its technology enables efficacy testing, mechanism-of-action studies, biomarker discovery, and safety assessment across dermatology, inflammation, aging, and regenerative medicine. BioHive also builds strategic biobanks of patient-derived samples to support precision medicine and translational research. By combining tissue engineering, advanced analytics, and customizable study design, BioHive helps partners reduce R&D risk, accelerate decision-making, and bring more predictive, ethical, and effective solutions to market.

BioHive offers advanced human skin organoid platforms and patient-derived biobanks for drug discovery, cosmetics testing, and translational research.


Cécile Nait

CEO & Founder

c.nait@biohive-innovations.com



bYoRNA



Oncology Rare diseases Infectious diseases

bYoRNA is developing a disruptive, patented technology for producing messenger RNA (mRNA) via yeast fermentation, an alternative to the current in vitro transcription (IVT) process. This approach will significantly reduce the immunogenicity of the mRNAs produced, improve their efficiency while allowing for better tissue targeting and diminishing the production cost by two orders of magnitude.

Current work focuses on validating the biological quality of the produced mRNAs, with results expected by mid-2026 in cell models (protein expression and functionality) and then in animal models (tolerance and biological activity).


"bYoRNA has raised \$10M+ in dilutive and non-dilutive funding and secured partnerships for proof-of-concepts on 3 critical indications with TRON, the mRNA research institute created by the founders of BIONTECH, as well as a leading animal pharma company and a major European rare disease institute.

Pascal Viguié

Chief Executive Officer

pascal@byorna.bio





Autoimmune diseases Neurodegenerative diseases

Cardio metabolic [More](#)

DeepLife leverages cell-type-specific digital twin models to pinpoint the most relevant disease indications for any therapeutic compound. At the core is TwinCell – a large-scale causal model of cell biology that identifies the molecular drivers of disease and how to reverse them. TwinCell combines these insight with large scale single-cell multi-omics data to build precise models of human cell types and their regulatory networks.

These digital twins replicate real cellular behavior, predicting preclinical outcomes and enabling researchers to explore disease mechanisms in silico. This approach uncovers how compounds act at the cell-type level, enhancing target validation, biomarker discovery and indication selection.

Applied across the drug development lifecycle, TwinCell accelerates decision making, reduces risk and improves translational relevance.

Jonathan Baptista

CEO & Co-founder

jonathan.baptista@deeplife.co



Oncology Infectious diseases Inflammatory

MABSilico is a leading TechBio company providing AI-based solutions for rapid antibody drug discovery. The company mitigates R&D risk by delivering computationally designed candidates within days, characterized in silico for epitope, affinity, and developability.

Its proprietary pipeline offers monoclonal, bispecific, and ADC leads available for out-licensing. Beyond its partnership with Yntoab in Korea and its end-to-end lead-to-production solution with Sartorius, MABSilico is executing a major US development strategy and actively seeking US partners to expand deployment of its platform.

Using NLP-driven competitive landscape analysis, MABSilico ensures freedom to operate, transforming discovery into a high-velocity engine for next-generation immunotherapies.

Vincent Puard

CEO

vincent.puard@mabsilico.com



Oncology Dermatology Neurology [More](#)


NETRI is an innovative industrial Techbio whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-Sensor (NaaS) suite to gain insights into the safety and efficacy of clinical and chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology, immunology, neurological disorders, neurotoxicity and dermatology.

Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world's first compartmentalized electrophysiology platform in a standard 96-well plate format – NeuroFluidics™ MEA – which serves as a data generation hub for its Digital Signature libraries of tested and reference compounds. To enable prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, Organ-on-chip hardware, AI-trained software, digital libraries and methods.

Thibault Honegger

CEO & Co-founder

thibault.honegger@netri.com



AI Oncology I & I Neurology


Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biological Artificial Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software.

At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.

Dinesh Divakaran

VP, Business Development

dinesh.divakaran@owkin.com



Neurology Psychiatry CNS

Theremia is an AI-powered solution transforming precision medicine in neurology and psychiatry. Leveraging the largest European CNS patient databases (+1.5 million patients) and its proprietary pharmacological knowledge graph (+20 million drug connections), Theremia develops predictive models of drug efficacy to optimize clinical trials, identify responsive patient subpopulations, and enable more targeted, safer therapies—accelerating market access and extending asset value for biotech and pharmaceutical companies.

Backed by €3 million from Eurazeo and Salica Investments, and incubated at Agoranov in Paris, Theremia collaborates with 20+ leading medical institutions across Europe and the US, with multiple ongoing proof-of-concept studies.

Iris Marechal

CEO & Co-founder

irismarechal@theremia.health



Genomics Medicine Gene Therapy Cell Therapy

WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y-Combinator, the company has established itself as a key player in genomic medicine innovation.


Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks. WhiteLab collaborates with major pharmaceutical companies (such as Sanofi), as well as leading academic institutions, and innovative biotech companies.

WhiteLab is a member of the prestigious French Tech 2030 program and part of Bayer Co.Lab in Cambridge (USA).

Nathan Lee

Head of Partnerships

nlee@whitelabgx.com



Sterilization Endoscopy Medical Devices

Aurora makes breakthrough low-temperature sterilizers for sensitive medical devices.

The sterilant is made of pure air gases, turned into plasmas (= northern lights). This technology paves the way to:

- the sterile reprocessing of complex medical devices in hospitals: GI endoscopes and echo-endoscopic probes
- environmentally friendly sterilization of medical devices manufactured by large medtech manufacturers


The company has been largely recognized for its unique technology and potential, as a France 2030 AMI-MIE, EIC Accelerator, and IPCEI Tech4Cure laureate.

Aurora's first sales highlight strong market traction, and the company expects even stronger momentum with CE marking expected in Q4 2026 and FDA approval by the end of 2026. This is why Aurora is aiming to raise capital by the end of this year to support its growth.

Thomas Parias

CEO & Founder

thomas.parias@aurora-sterilisation.com



Infectious diseases Women's health Antimicrobial Resistance

NG Biotech is a fully integrated diagnostics company specializing in lateral flow technologies.

The company designs, develops, and manufactures innovative diagnostic solutions, with end-to-end control spanning from early research and development through clinical validation and large-scale industrial deployment.

Headquartered and manufacturing in France, NG Biotech operates to the highest standards of clinical performance, quality assurance, and regulatory compliance, serving healthcare systems and partners worldwide.

NG Biotech is advancing the future of diagnostics by addressing critical unmet needs in the detection of antimicrobial resistance, emerging infectious diseases, and women's health. Through a new generation of rapid, reliable, and multiplex diagnostic tests, the company enables timely, actionable clinical decision-making where it has the greatest impact.

Milovan Stankov Puges

Chief Executive Officer

mstp@ngbiotech.com





EU market access Commercialization Pharma launch

AzurBio is the partner of choice for biopharma companies looking to launch their innovation in rare or serious diseases in the European market.

With a dual presence in the US and Europe, AzurBio supports North American companies in accessing the EU market by maximizing flexibility and minimizing operational burden.

Philippe Teboul

Chief Business Officer

teboul.philippe@azurbio.com



Regulatory strategy Market access Clinical development

Voisin Consulting Life Sciences (VCLS) is a global consulting organization, with customized CRO abilities dedicated to guiding innovators through the development of HealthTech products from concept to patient access.

VCLS supports innovative development like orphan drugs, ATMPs, Oncology, Immunology, Combination product and microbiome therapies, with 30 years of deep expertise to reduce time to key success, taking advantage of new regulations and interaction with Health Authorities.


With deep expertise, VCLS helps biotech and pharma design derisked, smarter, faster, and efficient development pathways.

VCLS experts optimize non-clinical, CMC, clinical, regulatory, and market access strategies to accelerate evidence generation and reduce time to key milestones, taking advantage of new regulations and interaction with Health Authorities.

Lori Kaiser

Business Development Director

lkaiser@voisinconsulting.com



mRNA-LNP manufacturing Continuous Manufacturing

Automated Production

Dillico developed the All-ScaleFlow manufacturing platform, an end-to-end automated continuous production system for m/sa/gRNA-LNP therapeutics with related digital tools and services. This solution enables efficient in silico process development for any mRNA therapeutic, leveraging a Performance Modeling Platform.

The continuous production is scale-up-free and can process batches ranging from preclinical or individualized medicine scale to large commercial scale. The All-ScaleFlow is a powerful tool to accelerate the advancement of m/sa/gRNA assets through the pipeline.

Christophe Bonneville

Chief Executive Officer

christophe.bonneville@dillico.com



ATMPs Cell therapy GMP manufacturing

EFS, France's sole public blood transfusion operator, is a key player in the bioproduction of advanced therapy medicinal products (ATMPs). Through its four French sites, EFS Bioproduction supports the development and manufacturing of the most innovative cell therapy products (MSCs, CAR-T, iPS, hESCs, HSCs, etc.). EFS also assists companies developing new bioproduction technologies or automation solution as we support the POC and transition to GMP scale.

This expertise is based on solid scientific, technical, and regulatory knowledge, combined with close collaboration with researchers, clinicians, and industrial partners. As a CDMO, the EFS supports the industrialization and production in accordance with Good Manufacturing Practices (GMP) of preclinical and clinical projects, serving patients awaiting therapeutic solutions.

Célia Mercier

Business Development Manager

celia.mercier@efs.sante.fr






Partnering intelligence External innovation BD&L platform

Deal is our industry-leading partnering intelligence platform that helps BD, R&D, Alliance Management and leadership teams structure the evaluation and management of external opportunities across the partnering life-cycle. The platform captures scientific and commercial evaluation data, enables efficient collaboration across teams, and creates a clear history of partnering evaluations and decisions.

By transforming fragmented opportunity data into structured intelligence, Deal unlocks AI-driven insights that help organizations surface patterns across evaluations, identify strategic gaps, and generate portfolio-level visibility, enabling leadership teams to answer critical partnering questions in minutes and make faster, more reliable decisions.

Alex Barker
President, Pharma & Na
alex.barker@inpart.io



Microscopy imaging Super resolution imaging

Organoids & 3D models

Inscoper provides high-performance super-resolution imaging solutions for Biopharma and CRO applications through its liveDRIM™ system. Optimized for organoids, 3D cell models, and high-content workflows, it delivers 100 nm resolution in thick, live samples without the typical trade-offs between speed, depth, and cell viability.

Inscoper also facilitates advanced microscopy workflows and custom OEM configurations. It helps generate the robust metrics needed for protocol development, and delivers the reproducible, analysis-ready data required to validate complex therapeutic approaches in diverse R&D environments.

Olivier Chanteux
Chief Executive Officer
olivier.chanteux@inscoper.com



France™



TOUR EIFFEL

312m of iron - symbol of the country of elegance. Charm is an attitude.

**MAKE IT
ICONIC**

choosefrance.fr

CHOOSE FRANCE



Choose France: a business environment designed to ease your European development

Reforms supporting businesses' competitiveness and the simplification of administrative procedures introduced since 2017

Thanks to a series of structural reforms undertaken since 2017, France is back in the game in Europe in terms of capital and labour taxation. At the end of 2024, the unemployment rate stood at 7.3%, nearly its lowest level in the past 40 years (7.1% in 1982). With growth assessed at 1.1% in 2024, the French economy has proved resilient. Growth of 0.7% is projected for 2025, taking into account the deteriorating international environment, in particular the effect of tariff increases on the French economy.

A FISCAL ENVIRONMENT FAVOURABLE TO INVESTMENT

As part of a macroeconomic competitiveness policy pursued since 2017, in addition to the reduced cost of labour and capital, taxes have been lowered by €52 billion, households and businesses combined.

For businesses, this reflects the gradual lowering of the corporate tax rate over five years, from 33% to 25%, as well as

the reduction of taxes on production by €10 billion per year since 2021.

The research tax credit, introduced in 1983 and increased in 2018, is the most generous R&D tax support scheme among OECD countries. The credit is permanent, and represents an average annual tax expenditure of €7.5 billion for the French government.

A TRANSFORMED SOCIAL MODEL

The successive and far-reaching labour law reforms carried out over recent years in France have given companies more flexibility and predictability, in particular by allowing them to:

→ Adjust work organization rules to meet the company's needs (working time, remuneration, mobility, etc.). In 2022, there was a 15% increase in the number of collective bargaining agreements signed.

→ Benefit from greater predictability regarding the termination of employment contracts thanks to the

introduction of a cap on compensation due in the event of wrongful dismissal, and a time limit of one year to contest a dismissal. Between 2010 and 2020, there was a 55.6% decrease in employment tribunal cases.

France has pursued a policy that promotes returning to and retaining employment, with new rules for unemployment benefits (minimum amount of time worked) and adjustment of the benefit payment period, as well as extending the contribution period for pensions and raising the retirement age from 62 to 64 for the majority of French employees.

WORKING TIME FAR FROM COMMON MISCONCEPTIONS:

→ 63% of employees worked more than 35 hours per week in 2020. The average weekly working time of management-level employees was 42.5 hours per week in 2021.

→ The maximum weekly working time is 48 hours in one week and 44 hours per week on average over 12 weeks. Overtime applies after 35 hours.

→ Labour costs have fallen thanks to a reduction in social security contributions representing a gain of €20 billion per year for companies, and thanks to several reduction mechanisms.

Moreover, hourly labour productivity is high: 65.2% in 2022, compared to 68.2% for Germany and 55.6% in the EU.



Boost your business with V.I.E

More than 10,000 businesses have already integrated the V.I.E program into their international business strategy since its launch!



A turnkey HR solution, **the V.I.E program enables French businesses to expand internationally** by assigning a young talent, aged 18 to 28 (French or a national of the European Economic Area), to a professional mission abroad, lasting from six to 24 months.

Assignments may involve:

- Studying and exploring new international markets
- Providing technical or commercial support to teams
- Identifying potential partners, agents, or distributors
- Supporting the creation and implementation of local structures

The advantages of the V.I.E program:

- **A turnkey solution:** The administrative, legal and social management of the V.I.E program is delegated to Business France.
- **A controlled budget:** The allowances paid to V.I.E talents are exempt from social security contributions. Eligible businesses can benefit from various financial support to reduce the budgetary impact of the V.I.E program.
- **A flexible HR system:** Variable duration, renewable assignments, up to 182 days of assignment on French territory, regional V.I.E covering up to eight countries. The V.I.E contract can be adapted to all projects!
- **A talent pool:** Available in a CV database of more than 70,000 candidates.

Learn more at businessfrance.fr/vie



Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France's companies, business image and nationwide attractiveness as an investment location, and also runs the V.I.E international internship program.

For more information, visit:
world.businessfrance.fr/north-america

North America

Jérôme Revole (Boston, MA)
Healthcare and Life Sciences Director
jerome.revole@businessfrance.fr

Ludmilla Potiron (Toronto, ON)
Business Unit Director
ludmilla.potiron@businessfrance.fr

Nam-Hee Lee (San Francisco, CA)
Business Trade Advisor
namhee.lee@businessfrance.fr

Sebastien Duprey (Houston, TX)
Business Trade Advisor
sebastien.duprey@businessfrance.fr

France

Aïssata Camara (Paris, France)
Project Manager
aissata.camara@businessfrance.fr

Elise Gasquet (Paris, France)
Project Manager
elise.gasquet@businessfrance.fr

Adrien Auge (Paris, France)
Partnerships Manager
adrien.auge@businessfrance.fr



Business France Healthcare
North America

